Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort

PloS One
Antonella d'Arminio MonforteIcona Foundation and HepaIcona Study Group

Abstract

Real-life data on access and response to direct antiviral agents (DAA) in HIV-HCV coinfected individuals are lacking. HCV viremic, HIV-positive patients from Icona and Hepaicona cohorts naïve to DAA by January 2013 were included. Access and predictors of starting DAA were evaluated. Switches of antiretroviral drugs at starting DAA were described. We calculated sustained virological response (SVR12) in those reaching 12 weeks after end-of-treatment (EOT), and defined treatment failure (TF) as discontinuation of DAA before EOT or non-SVR12. Statistical analyses included Kaplan-Meier curves, univariable and multivariable analyses evaluating predictors of access to DAA and of treatment outcome (non-SVR and TF). 2,607 patients included. During a median follow-up of 38 (IQR:30-41) months, 920 (35.3%) patients started DAA. Eligibility for reimbursement was the strongest predictor to access to treatment: 761/1,090 (69.8%) eligible and 159/1,517 (10.5%) non-eligible to DAA reimbursement. Older age, HIV-RNA≤50 copies/mL were associated to faster DAA initiation, higher CD4 count and HCV-genotype 3 with delayed DAA initiation in those eligible to DAA reimbursement. Up to 28% of patients (36% of those on ritonavir-boosted protease inhibitor...Continue Reading

References

Jul 25, 2009·The New England Journal of Medicine·John G McHutchisonUNKNOWN IDEAL Study Team
Apr 24, 2013·The New England Journal of Medicine·Eric LawitzEdward J Gane
Feb 24, 2015·JAMA : the Journal of the American Medical Association·Mark S SulkowskiThomas Podsadecki
Apr 26, 2015·Journal of Hepatology·UNKNOWN European Association for Study of Liver
May 20, 2015·Gastroenterology·Michael CharltonUNKNOWN SOLAR-1 Investigators
May 30, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Patrick R HarringtonJeffrey Murray
Jun 3, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Varun SaxenaNorah A Terrault
Jun 13, 2015·AIDS Patient Care and STDs·Rebecca CopeRamakrishna Prasad
Jun 26, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·UNKNOWN AASLD/IDSA HCV Guidance Panel
Jul 22, 2015·The New England Journal of Medicine·David L WylesUNKNOWN ALLY-2 Investigators
Jul 22, 2015·The New England Journal of Medicine·Susanna NaggieUNKNOWN ION-4 Investigators
Nov 18, 2015·The New England Journal of Medicine·John W Ward, Jonathan H Mermin
Jan 9, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sahar SaeedDavid Wong
Jun 19, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Philippe SogniLinda Wittkop
Sep 16, 2016·Lancet·Lionel PirothUNKNOWN ICONE Study Group

❮ Previous
Next ❯

Citations

Nov 24, 2018·Virology Journal·Antonio Di BiagioGiovanni Cenderello
Nov 2, 2019·PloS One·Ivan GardiniAndrea Marcellusi
Apr 13, 2020·Hepatology International·Maria Giovanna QuarantaUNKNOWN PITER Collaborating Group
Dec 12, 2018·World Journal of Hepatology·Dominique SalmonUNKNOWN ANRS CO13 Hepavih study Group
May 18, 2018·BMC Infectious Diseases·Simone LaniniUNKNOWN members of the Lazio Region HCV treatment group
Aug 21, 2021·Infectious Diseases of Poverty·Pablo RyanSalvador Resino

❮ Previous
Next ❯

Related Concepts

Related Feeds

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.